In a completed phase I/II study of Ieramilimab with or without the anti-PD-1 spartalizumab (PDR001) in 255 advanced solid tumor patients, including RCC, ieramilimab was well tolerated and showed modest antitumor activity in the combination arm (n = 121, 3 had a complete response, 10 had a partial response, and 35 had stable disease) including patients pre-treated with anti-PD-1/PD-L1 [63]. Here, PDCD1 is linked to renal cell carcinoma.